Answers are grounded in this paper and cite their sources.
Background: The aims of this study are to estimate retention in HIV PrEP care in a large Italian centre and identify factors associated with discontinuation. Setting: Tertiary infectious diseases centre in Milan, Italy. Methods: This is a retrospective study including PrEP users with ≥1 follow-up visit between July 2017-January 2025; follow-up through June 2025. Retention was defined as ongoing follow-up at the centre or confirmed transfer while continuing PrEP; discontinuation as loss to follow-up (>12 months) or documented decision to stop PrEP. Users’ characteristics were compared using non-parametrical tests. Kaplan-Meier method was used to assess retention probability. Results: Among 1.781 PrEP users, 1.612 with ≥1 follow-up visit were included (median follow-up 1.7 years, IQR=0.7–2.9). Regimens at initiation were daily FTC/TDF (41.5%), on-demand FTC/TDF (58.3%), and long-acting cabotegravir (0.1%). Over follow-up, 77 users switched to cabotegravir. At data-freeze, 1142/1612 (70.8%) were in active follow-up, 22/1612 (1.4%) had transferred, 357/1612 (22.2%) were lost to follow-up, and 91/1612 (5.7%) had discontinued PrEP. The probability of retention was 84.7% (95%CI=82.9-86.6) at 1 year and 74.9% (95%CI=72.6-77.4) at 2 years. Older age (retained: 35.5 years, IQR=30.7-42.2 vs not retained: 32.9, IQR=28.6-38.0, p<0.001), DoxyPEP use (178/1164, 15.3% vs 17/448, 3.8%, p<0.001) and the number of STIs over follow-up (IRR 1.14, 95%CI=1.02-1.28, p=0.018) were associated with higher retention. Conclusion: Retention in this Italian PrEP centre was moderately high. Older individuals and DoxyPEP users were more likely to be retained. These findings support targeted retention strategies and integrated sexual health services to reduce disengagement from PrEP care.
No takes yet. Share an insight, caveat, or question.
Raccagni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: